Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions

Abstract

This invention is the coadministration of ACAT and MMP inhibitors for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regression in a mammal.

Description

Background of the invention [0001] Enzymes known as native matrix metalloproteinases (MMPs) are a class of naturally occurring enzymes found in most mammals. They are zinc proteases that hydrolyze collagen, proteoglycans, and glycoproteins. These types include gelatinase A and B, stromelysin-1 and -2, fibroblastic collagenase, neutrophil collagenase, stromelysin, metalloelastase, and interstitial collagenase. These enzymes have been linked to many diseases caused by damage to connective tissue, such as rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis, and even tumor metastasis. MMP expression in atherosclerosis in White A., Bocan T.M.A., Boxer P.A., Peterson J.T., Schrier D. Presentation of second-generation matrix metalloproteinase inhibitors for treatment, Curr.Phar.Design 3:45-58 (1997). To date, matrix metalloproteinase inhibitors have not been used with ACAT inhibitors. [0002] MMP inhibitors and their preparation are taught in US Patent Applica...

AI Technical Summary

Problems solved by technology

To date, matrix metalloproteinase inhibitors have not been used with ACAT inhibitors